Naglazyme 5mg/5ml (Galsulfase Vials) 5mg/5ml

Naglazyme 5mg/5ml (Galsulfase) is an enzyme replacement therapy for mucopolysaccharidosis type VI (MPS VI). This 5mg/5ml vial formulation supports lysosomal storage disorder management. Store at 2-8°C to maintain potency. Consult your healthcare provider for suitability.

Strength

5mg/5ml

Pack Size

Storage

2-8°

Manufacturer / TM Owner

BioMarin International Limited

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Galsulfase is used to treat mucopolysaccharidosis type VI, a rare genetic disorder affecting enzyme function. This enzyme replacement therapy helps manage symptoms by addressing the underlying metabolic cause. It is prescribed for patients with confirmed MPS VI diagnoses. The 5mg/5ml vial form provides the necessary dose for infusion therapy.

Side Effects

After administration, galsulfase works gradually to break down accumulated glycosaminoglycans in cells. Patients may notice improved mobility and reduced joint stiffness over time. Some individuals report better endurance during daily activities following regular treatment. Effects vary based on individual response and disease progression.

Precautions & Warnings

Store Naglazyme vials refrigerated between 2-8°C and protect from light. Avoid freezing or shaking the vial. Always check the solution for particles or discoloration before use. Keep out of reach of children and pets. Discard any unused portion according to local guidelines.

Avoid Interactions

No specific drug interactions have been established for galsulfase. However, other medications should be reviewed by your healthcare provider before starting treatment. Caution is advised when combining with drugs affecting lysosomal function. Always disclose all medications to your physician.

References

Frequently Asked Questions

Galsulfase is an enzyme replacement therapy for mucopolysaccharidosis type VI (MPS VI), a lysosomal storage disorder.

Naglazyme is given as an intravenous infusion by healthcare professionals in a clinical setting.

No, Naglazyme must be refrigerated between 2-8°C and protected from light.

Possible effects include infusion reactions, joint pain, or respiratory issues; consult your doctor if symptoms occur.

Yes, this medication requires a prescription from a licensed healthcare provider.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.